NCT02329899
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, Hemorrhagic Disorders
- Locations
-
- Haemostasis unit, University Hospitals of Geneva Geneva, Switzerland
Clinical trial condition
Hemorrhagic Disorders
Explore clinical trials studying Hemorrhagic Disorders. Study availability and eligibility vary by location and protocol.
49 public trials
9 recruiting studies
Hemorrhagic Disorders trial results
NCT01558739
- Conditions
- Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +11 more
- Locations
-
- Novartis Investigative Site Cardiff, Wales, United Kingdom
- Novartis Investigative Site Bournemouth, United Kingdom
- Novartis Investigative Site East Yorkshire, United Kingdom
- Novartis Investigative Site Edinburgh, United Kingdom
NCT00079716
- Conditions
- Blood Coagulation Disorders, Blood Protein Disorders, Cardiovascular Diseases, +14 more
- Locations
-
- James R. Berenson M.D., Inc. West Hollywood, California, United States
- Rocky Mountain Cancer Center Denver, Colorado, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- Cornell University New York, United States
NCT00525447
- Conditions
- Blood Coagulation Disorders, Blood Protein Disorders, Cardiovascular Diseases, +14 more
- Locations
-
- Rocky Mountain Cancer Center Denver, Colorado, United States
- H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
NCT00725634
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
- Locations
-
- Investigational Site 2 Scottsdale, Arizona, United States
- Investigational Site 3 Columbus, Ohio, United States
- Investigational Site 1 San Antonio, Texas, United States
NCT00000582
- Conditions
- Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
- Locations
-
Not specified
Active, Not Recruiting
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
NCT03162536
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
- Locations
-
- Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
- UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
- Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
- University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
Active, Not Recruiting
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734
- Conditions
- Anemia, Blood Platelet Disorders, Bone Marrow Diseases, +11 more
- Locations
-
- University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center Birmingham, Alabama, United States
- Mayo Clinic Hospital Phoenix, Arizona, United States
- City of Hope Duarte, California, United States
- USC Norris Comprehensive Cancer Center Los Angeles, California, United States
Active, Not Recruiting
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
NCT06224907
- Conditions
- Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Cardiovascular Diseases, +9 more
- Locations
-
- Asahikawa Medical University Hospital Hokkaido, Asahikawa, Japan
- Saitama Medical University Hospital Saitama, Iruma-gun, Japan
- Nagoya University Hospital Aichi, Nagoya, Japan
- Tokyo Medical University Hospital Tokyo, Shinjuku-ku, Japan